1-8 of 8
smoldering myeloma
Close
Sort by
Journal Articles

Manasanch EE, Han G, Mathur R, et al. A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis. Blood Adv. 2019;3(15):2400-2408.

Journal: Blood Advances
Blood Adv (2019) 3 (18): 2712.
https://doi.org/10.1182/bloodadvances.2019000881
Published: 2019
Journal Articles

A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis

Elisabet E. Manasanch, Guangchun Han, Rohit Mathur, Yun Qing, Zheng Zhang, Hans Lee, Donna M. Weber, Behrang Amini, Zuzana Berkova, Karina Eterovic, Shaojun Zhang, Jianhua Zhang, Xingzhi Song, Xizeng Mao, Margaret Morgan, Lei Feng, Veera Baladandayuthapani, Andrew Futreal, Linghua Wang, Sattva S. Neelapu, Robert Z. Orlowski
Journal: Blood Advances
Blood Adv (2019) 3 (15): 2400–2408.
https://doi.org/10.1182/bloodadvances.2019000300
Published: 2019
Includes: Supplemental data
Journal Articles

Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma

Clinical Trials & Observations
Mohammed A. Aljama, M. Hasib Sidiqi, Arjun Lakshman, Angela Dispenzieri, Dragan Jevremovic, Morie A. Gertz, Martha Q. Lacy, Francis K. Buadi, David Dingli, Eli Muchtar, Amie L. Fonder, Suzanne R. Hayman, Miriam A. Hobbs, Wilson I. Gonsalves, Rahma Warsame, Taxiarchis V. Kourelis, Yi Lisa Hwa, Prashant Kapoor, Nelson Leung, Ronald S. Go, Robert A. Kyle, S. Vincent Rajkumar, Shaji K. Kumar
Journal: Blood Advances
Blood Adv (2018) 2 (22): 3149–3154.
https://doi.org/10.1182/bloodadvances.2018024794
Published: 2018
Journal Articles

Timing of treatment of smoldering myeloma: early treatment

Clinical Trials & Observations
María-Victoria Mateos, Verónica González-Calle
Journal: Blood Advances
Blood Adv (2018) 2 (21): 3045–3049.
https://doi.org/10.1182/bloodadvances.2018021220
Published: 2018
Journal Articles

Timing of treatment of smoldering myeloma: delay until progression

Clinical Trials & Observations
Shaji K. Kumar
Journal: Blood Advances
Blood Adv (2018) 2 (21): 3050–3053.
https://doi.org/10.1182/bloodadvances.2018021238
Published: 2018
Journal Articles

Wu V, Moshier E, Leng S, et al. Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling. Blood Adv . 2018;2(12):1470-1479.

Journal: Blood Advances
Blood Adv (2018) 2 (17): 2186.
https://doi.org/10.1182/bloodadvances.2018024281
Published: 2018
Journal Articles

Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling

Clinical Trials & Observations
Vernon Wu, Erin Moshier, Siyang Leng, Bart Barlogie, Hearn Jay Cho, Sundar Jagannath, Deepu Madduri, Madhu Mazumdar, Samir Parekh, Ajai Chari
Journal: Blood Advances
Blood Adv (2018) 2 (12): 1470–1479.
https://doi.org/10.1182/bloodadvances.2018016998
Published: 2018
Journal Articles

Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma

Clinical Trials & Observations
Sham Mailankody, Dickran Kazandjian, Neha Korde, Mark Roschewski, Elisabet Manasanch, Manisha Bhutani, Nishant Tageja, Mary Kwok, Yong Zhang, Adriana Zingone, Laurence Lamy, Rene Costello, Candis Morrison, Malin Hultcrantz, Austin Christofferson, Megan Washington, Martin Boateng, Seth M. Steinberg, Maryalice Stetler-Stevenson, William D. Figg, Elli Papaemmanuil, Wyndham H. Wilson, Jonathan J. Keats, Ola Landgren
Journal: Blood Advances
Blood Adv (2017) 1 (22): 1911–1918.
https://doi.org/10.1182/bloodadvances.2017005934
Published: 2017